News » Visby Medical Appoints Everett Cunningham to Board of Directors

05/25/2022Press Release

Visby Medical Appoints Everett Cunningham to Board of Directors

Visby Medical today announced Everett Cunningham has been appointed to the company’s Board of Directors.

Visby Medical Appoints Everett Cunningham to Board of Directors

SAN JOSE, Calif., May 25, 2022Visby Medical™, a leading medical diagnostic company, today announced Everett Cunningham has been appointed to the company’s Board of Directors. Cunningham is currently Chief Commercial Officer at Exact Sciences and brings 30 years of commercial experience in pharmaceuticals and molecular diagnostics to the company’s board.

“I am thrilled to welcome Everett to the Visby team,” said Visby Medical Founder and CEO Adam de la Zerda, Ph.D. “Everett is a dynamic executive with deep experience across the pharmaceutical and diagnostic industries. I look forward to his partnership and leadership; he will undoubtedly add tremendous value to the company during this exciting phase of growth.”

Cunningham brings a wealth of knowledge from leadership roles in large organizations, where he combined his commitment to excellence and responsibility with his passion for improving healthcare quality, access and affordability. He has been serving as Chief Commercial Officer at Exact Sciences since 2021. Previously, he served as President & CEO of GE Healthcare’s U.S. & Canada region, and was Senior Vice President, Commercial, at Quest Diagnostics.

“Visby has shown great success as an industry leader in infectious disease diagnostics with the world’s first instrument-free, single-use PCR platform to accurately and rapidly test for serious infections,” said Cunningham. “I am honored to join the board of such an innovative company that is dedicated to demonstrating a meaningful change in the diagnosis and treatment of infectious diseases.”

About Visby Medical™
Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The Company’s proprietary technology development program culminated in the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. Visby Medical is accelerating the delivery of fast and accurate, palm-sized PCR diagnostics to the point of care, and eventually for use at home.

For more information, visit www.visbymedical.com. Follow Visby Medical on LinkedInFacebook, and Twitter.

Media Contact
Doug Hochstedler
press@visby.com

Read more articles & insights

04/05/2024Viewpoint

The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

In light of the rising rates of sexually transmitted infections (STIs), urgent care clinics have found themselves at a crucial crossroads. PCR (Polymerase Chain Reaction) testing at the point of care emerges as a potential game-changer.

Read More
The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

03/14/2024Viewpoint

Understanding the Financial Impact of PCR Point of Care Testing for STIs

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

Read More
Understanding the Financial Impact of PCR Point of Care Testing for STIs

03/07/2024Viewpoint

5 Frequently Asked Questions on Implementing PCR into Urgent Care

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

Read More
5 Frequently Asked Questions on Implementing PCR into Urgent Care

02/21/2024Press Release

CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million to develop a portable polymerase chain reaction (PCR) test that can detect gonorrhea and assess its susceptibility to ciprofloxacin.

Read More
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test